We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-18.65%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$626M
AUM Growth
-$126M
Cap. Flow
+$63M
Cap. Flow %
10.07%
Top 10 Hldgs %
43.21%
Holding
89
New
9
Increased
11
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
OMER icon
Omeros
OMER
+$24.5M
2
SAGE
Sage Therapeutics
SAGE
+$14.8M
3
RMTI icon
Rockwell Medical
RMTI
+$10.1M
4
ZYNE
Zynerba Pharmaceuticals, Inc
ZYNE
+$8.75M
5
HRTX icon
Heron Therapeutics
HRTX
+$8.19M

Top Sells

Rank Stock Value
1
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$41.8M
2
KERX
Keryx Biopharmaceuticals Inc
KERX
+$8.24M
3
NGNE icon
Neurogene
NGNE
+$1.5M
4
FOLD
Amicus Therapeutics
FOLD
+$784K
5
NSTG
NanoString Technologies, Inc.
NSTG
+$627K

Sector Composition

Rank Sector Weight
1 Healthcare 80.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
26
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$8.78M 1.4%
+255,000
New +$7.71M
RMTI icon
27
Rockwell Medical
RMTI
$28.4M
$8.52M 1.36%
10,045
+6,954
+225% +$10.1M
ADXS
28
DELISTED
Advaxis Inc
ADXS
$8.18M 1.31%
53,333
– –
FWP
29
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$7.89M 1.26%
47,867
+11,438
+31% +$2.4M
LPCN icon
30
Lipocine
LPCN
$17.5M
$7.89M 1.26%
39,216
– –
MCRB icon
31
Seres Therapeutics
MCRB
$46.8M
$7.41M 1.18%
12,500
+10,000
+400% +$8.16M
AGEN
32
Agenus
AGEN
$312M
$7.17M 1.15%
79,431
– –
NERV icon
33
Minerva Neurosciences
NERV
$185M
$6.01M 0.96%
143,130
-2
-0% -$92
RGLS
34
DELISTED
Regulus Therapeutics
RGLS
$5.86M 0.94%
7,471
– –
CRIS icon
35
Curis
CRIS
$9.78M
$5.32M 0.85%
1,316
– –
ZYNE
36
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$5.1M 0.82%
+356,600
New +$8.75M
XLRN
37
DELISTED
Acceleron Pharma
XLRN
$4.98M 0.8%
200,000
– –
ATRA icon
38
Atara Biotherapeutics
ATRA
$75.5M
$4.72M 0.75%
6,000
+4,000
+200% +$4.88M
APTO
39
DELISTED
Aptose Biosciences, Inc.
APTO
$4.71M 0.75%
2,404
– –
INDP icon
40
Indaptus Therapeutics
INDP
$172M
$4.48M 0.72%
+357
New +$4.69M
NKTR icon
41
Nektar Therapeutics
NKTR
$2.39B
$4.36M 0.7%
26,500
– –
DERM
42
DELISTED
Dermira, Inc.
DERM
$3.97M 0.63%
170,000
– –
EPRS
43
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
$3.96M 0.63%
896,600
– –
ARRY
44
DELISTED
Array Biopharma Inc
ARRY
$3.88M 0.62%
850,000
– –
KITE
45
DELISTED
Kite Pharma, Inc.
KITE
$3.83M 0.61%
68,800
– –
RGNX icon
46
Regenxbio
RGNX
$620M
$3.45M 0.55%
+156,741
New +$4M
EPZM
47
DELISTED
Epizyme, Inc
EPZM
$3.42M 0.55%
266,250
– –
KPTI icon
48
Karyopharm Therapeutics
KPTI
$43.5M
$3.17M 0.51%
20,066
– –
CYAD
49
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
$3.14M 0.5%
75,000
– –
IOVA icon
50
Iovance Biotherapeutics
IOVA
$1.82B
$2.88M 0.46%
499,815
– –
1
2
3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q3 2015 Portfolio in Review

As of Q3 2015, Cormorant Asset Management held 89 positions worth $626M, down 17% from $752M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Cormorant Asset Management deployed $63M of net new capital in Q3 2015, opening 9 new positions and adding to 11 existing holdings. Its largest new stake was Sage Therapeutics: 240,000 shares worth $10.2M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 74% a quarter earlier.

On the sell side, the largest reduction was Neurogene, an estimated $1.5M trimmed.

  • Cormorant Asset Management's largest Q3 2015 buy was Sage Therapeutics: 240,000 shares worth $10.2M.
  • Cormorant Asset Management added most to Omeros in Q3 2015, an estimated $24.5M increase.
  • Cormorant Asset Management's biggest Q3 2015 reduction was Neurogene, cutting an estimated $1.5M.
  • Cormorant Asset Management fully exited RECEPTOS INC COM STK (DE) in Q3 2015, selling an estimated $41.8M.
  • Cormorant Asset Management's ten largest holdings make up 43% of its $626M portfolio in Q3 2015.
  • Cormorant Asset Management opened 9 new positions and closed 2 in Q3 2015.
  • Cormorant Asset Management's portfolio value fell 17% quarter-over-quarter to $626M.

Based on Cormorant Asset Management's 13F filing for Q3 2015, filed 16 Nov 2015.